US company Catalent, which has its UK headquarters in Swindon, has acquired the Vaccine Manufacturing and Innovation Centre, currently under construction at Harwell in Oxfordshire.
Catalent plans to invest up to £120m to complete and equip the building which will employ more than 400 people and support public and private organisations seeking to develop and manufacture biotherapeutics.
“This acquisition allows Catalent to collaborate with the rich academic and biomedical science community centred around Oxford, with its world-class talent, and will result in a facility that provides opportunities to transform innovation into real treatments for patients across the United Kingdom, Europe, and beyond,” the company said.
-(2).png?sfvrsn=3b7e3050_0){kind=logo}
